-
Mashup Score: 7FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for ES-SCLC | Docwire News - 12 day(s) ago
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to sacituzumab govitecan-hziy (Trodelvy®) for extensive-stage small cell lung cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3FDA Issues Complete Response Letter for Subcutaneous Amivantamab in NSCLC | Docwire News - 12 day(s) ago
The Complete Response Letter “is related to observations as part of a standard pre-approval inspection at a manufacturing facility,” according to Johnson & Johnson officials.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📄 The US FDA has issued a Complete Response Letter for the Biologics License Application for subcutaneous amivantamab in NSCLC, according to Johnson & Johnson officials. ➡️ Learn more about the letter and the next steps: https://t.co/xs6BiSv8x2 #lcsm #NSCLC #LungCancer https://t.co/JtUVhh3QXb
-
-
Mashup Score: 2Implementing the Rural Appalachian Lung Cancer Screening Initiative: Dr. Gieske Shares Insights | Docwire News - 13 day(s) ago
Michael R. Gieske, MD, of the St. Elizabeth Cancer Center, discusses the Rural Appalachian Lung Cancer Screening Initiative at IASLC 2024 World Conference on Lung Cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Don't miss this interview with @mrgieske, who joined us to discuss his work exploring community perceptions & practices to inform lung cancer screening interventions. ➡️ Watch: https://t.co/Lj7LQCcepq #lcsm #LungCancer #NSCLC #SCLC #WCLC24 https://t.co/n7i3DOPfMm
-
-
Mashup Score: 3FDA Approves Ensartinib for ALK-Positive Locally Advanced or Metastatic NSCLC | Docwire News - 13 day(s) ago
The U.S. Food and Drug Administration has approved ensartinib (Ensacove) for adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGULATORY UPDATE: The FDA has approved ensartinib for adults with ALK-positive locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor. ➡️ Learn more: https://t.co/EZ8n6O4ckc #NSCLC #lcsm #ALK https://t.co/FsawLzXPU9
-
-
Mashup Score: 2Mark Your Calendar: Application Window Opens for LUNGevity Research Awards on January 13, 2025 - 14 day(s) ago
Research is central to improving outcomes of people diagnosed with and living with lung cancer. In 2025, LUNGevity is proud to continue our commitment to developing and sustaining a vibrant workforce in thoracic oncology.
Source: www.linkedin.comCategories: General Medicine News, Partners & KOLsTweet-
RT @LUNGevity: Mark Your Calendar: Application Window Opens for LUNGevity Research Awards on January 13, 2025! https://t.co/MoUiX8N5ou
-
-
Mashup Score: 4
The US Food and Drug Administration (FDA) has approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC).
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 REGUALTORY UPDATE: The US Food and Drug Administration has approved durvalumab for adults with LS-SCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ➡️ Learn more: https://t.co/xv5SVGZG9j #SCLC #LCSM https://t.co/dj7fwVAB2F
-
-
Mashup Score: 0Phase 2 Portion of Acclaim-3 Trial of Quaratusugene Ozeplasmid Plus Atezolizumab in ES-SCLC Opens | Docwire News - 15 day(s) ago
The Acclaim-3 trial is evaluating quaratusugene ozeplasmid gene therapy (Reqorsa) plus atezolizumab (Tecentriq) as a maintenance therapy for extensive stage small cell lung cancer.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 The phase 1 dose escalation portion of the Acclaim-3 clinical trial has been completed, with an approval for opening the phase 2 expansion portion of the trial, according to an announcement from @genprex. ➡️ Learn more about the trial: https://t.co/B7tAipjPAM #SCLC #lcsm https://t.co/H5MUkZGQRz
-
-
Mashup Score: 0American Lung Association’s Chief Mission Officer Discusses ‘State of Lung Cancer’ Report | Docwire News - 15 day(s) ago
Deborah Brown, Chief Mission Officer for the American Lung Association, joined Lung Cancers Today to discuss the association’s 2024 “State of Lung Cancer” report.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 Have you seen the latest "State of Lung Cancer" report? ⭐ Don't miss this interview with @LungAssociation Chief Mission Officer Deborah Brown, who shares key data and actionable findings from the report. ➡️ Watch now: https://t.co/fMWUiktzwR #lcsm #NSCLC #SCLC https://t.co/7LPJqkrhXz
-
-
Mashup Score: 2How Bone Metastasis Impacts NSCLC Outcomes With Immune Checkpoint Inhibitors | Docwire News - 16 day(s) ago
The retrospective analysis reaffirmed evidence from CCTG BR.34 that showed bone metastasis was associated with worse outcomes in ICI-treated NSCLC, with or without chemotherapy.
Source: docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
🫁 How does bone metastasis influence outcomes with immune checkpoint inhibitors in NSCLC? 📋 A retrospective analysis of the CCTG BR.34 trial by a team from @penn_state provided insights. ➡️ Learn more: https://t.co/pquZChpbck #NSCLC #lcsm https://t.co/5eywP6S2nI
-
-
Mashup Score: 9
The four-year grant is for $2.5 million and will fund a project titled, “Immune elimination of drug-tolerant persister cells in oncogene-driven lung cancer.”
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 ICYMI: A project led by @DavidBarbie8 of @DFarberThoracic, @DanaFarber is the first to receive the @IASLC @lcrf_org Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award. ➡️ Learn more: https://t.co/LS9wbbN5In #lcsm #LCAM #LungCancer https://t.co/2YiinZ1qN8
-
📰 REGULATORY UPDATE: The US FDA has granted Breakthrough Therapy Designation to sacituzumab govitecan as a treatment for adults with ES-SCLC whose disease has progressed on or after platinum-based chemotherapy. ➡️ Learn more: https://t.co/OWQtoXUtD2 #lcsm #SCLC https://t.co/5EWrVNTg5e